National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Last Modified: 3/31/2009     First Published: 5/23/2003  
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Natural History and Genetic Study of Patients With Von Hippel-Lindau Syndrome and Pancreatic Lesions

Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information
Registry Information

Alternate Title

Diagnostic and Genetic Study to Identify Pancreatic Lesions in Patients With Von Hippel-Lindau Syndrome

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedBiomarker/Laboratory analysis, Diagnostic, Natural history/EpidemiologyClosed12 and overNCINCI-03-C-0145
NCT00062166

Objectives

  1. Identify pancreatic lesions (e.g., simple cysts, microcystic adenomas, neuroendocrine tumors, or other solid lesions of the pancreas) in patients with von Hippel-Lindau syndrome (VHL).
  2. Follow patients with VHL and pancreatic manifestations by serial examination with non-invasive imaging studies (e.g., CT scan, MRI, and/or abdominal ultrasound).
  3. Correlate rate of lesion growth with clinical measures of disease progression (e.g., symptoms) in patients with solid lesions of the pancreas.
  4. Determine VHL mutation status and subtype the mutations for potential correlation with disease severity in these patients.
  5. Obtain tissue from the pancreatic lesions of these patients for genetic analysis, including comparative genomic hybridization, tissue proteomics, and cDNA microarray analysis.
  6. Determine the time from initial presentation with pancreatic tumors to the time that surgery is recommended in these patients.

Entry Criteria

Disease Characteristics:

  • Diagnosis of von Hippel-Lindau syndrome (VHL) by the Urologic Oncology Branch using germ line analysis OR clinical criteria and family history


  • Must have at least 1 of the following pancreatic manifestations of VHL documented by a non-invasive imaging study:
    • Pancreatic cyst(s)
    • Solid lesions suspicious for microcystic adenoma(s)
    • Solid enhancing lesions suspicious for pancreatic neuroendocrine tumor(s)
    • Any other solid lesion(s) of the pancreas


Prior/Concurrent Therapy:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Patient Characteristics:

Age

  • 12 and over

Performance status

  • Not specified

Life expectancy

  • Not specified

Hematopoietic

  • Not specified

Hepatic

  • Not specified

Renal

  • Not specified

Other

  • Willing to return to the National Institutes of Health for follow-up
  • Willing to undergo serial non-invasive imaging

Expected Enrollment

300

A total of 300 patients will be accrued for this study within 5 years.

Outline

Patients undergo non-invasive imaging studies (e.g., CT scan with contrast, MRI, and/or abdominal ultrasound). Blood and urine samples are collected for laboratory analysis. Blood samples are also drawn for genetic germ line mutational analysis.

All patients are offered genetic counseling.

Patients with cystic disease of the pancreas only (no solid lesions) are followed with non-invasive imaging studies at least every 2 years.

Patients with solid lesions of the pancreas that are suspicious for pancreatic neuroendocrine tumors (PNETs) and have not reached size criteria for surgery are followed annually with CT scans and MRI.

Patients with solid lesions of the pancreas that are suspicious for PNETs and have reached size criteria for surgery or are symptomatic for PNETs may undergo surgical management. Patients with cystic disease who develop symptoms attributable to the cysts may also undergo surgical management.

In patients who undergo surgical resection, tissue is removed for further genetic analysis, including comparative genomic hybridization, cDNA microarray analysis, and tissue proteomics.

Trial Contact Information

Trial Lead Organizations

NCI - Center for Cancer Research

Steven Rosenberg, MD, PhD, Principal investigator
Ph: 301-496-4164
Email: sar@nih.gov

Registry Information
Official Title Evaluation of the Natural History and Management of Pancreatic Lesions Associated with Von Hippel-Lindau
Trial Start Date 2003-04-11
Registered in ClinicalTrials.gov NCT00062166
Date Submitted to PDQ 2003-04-28
Information Last Verified 2008-11-30

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov